Floyd K - Search Results

1

OX40 is a potent immune-stimulating target in late-stage cancer patients.

Curti BD, Kovacsovics-Bankowski M, Morris N, Walker E, Chisholm L, Floyd K, Walker J, Gonzalez I, Meeuwsen T, Fox BA, Moudgil T, Miller W, Haley D, Coffey T, Fisher B, Delanty-Miller L, Rymarchyk N, Kelly T, Crocenzi T, Bernstein E, Sanborn R, Urba WJ, Weinberg AD. Curti BD, et al. Among authors: floyd k. Cancer Res. 2013 Dec 15;73(24):7189-7198. doi: 10.1158/0008-5472.CAN-12-4174. Epub 2013 Oct 31. Cancer Res. 2013. PMID: 24177180 Free PMC article. Clinical Trial.

2

gp100(209-2M) peptide immunization of human lymphocyte antigen-A2+ stage I-III melanoma patients induces significant increase in antigen-specific effector and long-term memory CD8+ T cells.

Walker EB, Haley D, Miller W, Floyd K, Wisner KP, Sanjuan N, Maecker H, Romero P, Hu HM, Alvord WG, Smith JW 2nd, Fox BA, Urba WJ. Walker EB, et al. Among authors: floyd k. Clin Cancer Res. 2004 Jan 15;10(2):668-80. doi: 10.1158/1078-0432.ccr-0095-03. Clin Cancer Res. 2004. PMID: 14760090

3

Phenotype and functional characterization of long-term gp100-specific memory CD8+ T cells in disease-free melanoma patients before and after boosting immunization.

Walker EB, Haley D, Petrausch U, Floyd K, Miller W, Sanjuan N, Alvord G, Fox BA, Urba WJ. Walker EB, et al. Among authors: floyd k. Clin Cancer Res. 2008 Aug 15;14(16):5270-83. doi: 10.1158/1078-0432.CCR-08-0022. Clin Cancer Res. 2008. PMID: 18698047 Free PMC article. Clinical Trial.

4

Characterization of the class I-restricted gp100 melanoma peptide-stimulated primary immune response in tumor-free vaccine-draining lymph nodes and peripheral blood.

Walker EB, Miller W, Haley D, Floyd K, Curti B, Urba WJ. Walker EB, et al. Among authors: floyd k. Clin Cancer Res. 2009 Apr 1;15(7):2541-51. doi: 10.1158/1078-0432.CCR-08-2806. Epub 2009 Mar 24. Clin Cancer Res. 2009. PMID: 19318471 Clinical Trial.

5

Immunological monitoring of patients with melanoma after peptide vaccination using soluble peptide/HLA-A2 dimer complexes.

Hu HM, Dols A, Meijer SL, Floyd K, Walker E, Urba WJ, Fox BA. Hu HM, et al. Among authors: floyd k. J Immunother. 2004 Jan-Feb;27(1):48-59. doi: 10.1097/00002371-200401000-00005. J Immunother. 2004. PMID: 14676633

6

Dual anti-OX40/IL-2 therapy augments tumor immunotherapy via IL-2R-mediated regulation of OX40 expression.

Redmond WL, Triplett T, Floyd K, Weinberg AD. Redmond WL, et al. Among authors: floyd k. PLoS One. 2012;7(4):e34467. doi: 10.1371/journal.pone.0034467. Epub 2012 Apr 4. PLoS One. 2012. PMID: 22496812 Free PMC article.

7

Polychromatic flow cytometry: a rapid method for the reduction and analysis of complex multiparameter data.

Petrausch U, Haley D, Miller W, Floyd K, Urba WJ, Walker E. Petrausch U, et al. Among authors: floyd k. Cytometry A. 2006 Dec 1;69(12):1162-73. doi: 10.1002/cyto.a.20342. Cytometry A. 2006. PMID: 17089357 Free article. Clinical Trial.

8

The effectiveness of sealants in pediatric patients.

Walker J, Floyd K, Jakobsen J. Walker J, et al. Among authors: floyd k. ASDC J Dent Child. 1996 Jul-Aug;63(4):268-70. ASDC J Dent Child. 1996. PMID: 8893980

9

A survey on the use of mouthguards and associated oral injuries in athletics.

Alexander D, Walker J, Floyd K, Jakobsen J. Alexander D, et al. Among authors: floyd k. Iowa Dent J. 1995 Apr;81(2):41, 43-4. Iowa Dent J. 1995. PMID: 9522704 No abstract available.

10

The effectiveness of preventive resin restorations in pediatric patients.

Walker J, Floyd K, Jakobsen J, Pinkham JR. Walker J, et al. Among authors: floyd k. ASDC J Dent Child. 1996 Sep-Oct;63(5):338-40. ASDC J Dent Child. 1996. PMID: 8958345

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

293 results

Search Page